16 September 2026 editorial review · Item
Once-weekly insulin icodec (Awiqli): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Once-weekly insulin icodec (Awiqli)
Scope and findings:
- EMA Awiqli EPAR confirms adultT1/T2 authorization and higher hypoglycemia inT1;T1 initiation only with clear weekly-dosing benefit. Does not establish all-market availability or US indication.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.